4D Molecular Therapeutics (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced presentations at the 2
On April 1, 2024, Chief Legal Officer Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) according to a recent SEC Filing.